Vaxart value goal lowered to $1.50 from $6 at B. Riley
B. Riley analyst Mayank Mamtani lowered the agency’s value goal on Vaxart to $1.50 from $6 and retains a Impartial score on the shares. The goal drop displays a extra conservative estimate of ramp-up of Norovirus and peak market penetration from 35% to 24%, Mamtani tells traders in a analysis notice.
Revealed first on TheFly
See as we speak’s best-performing shares on TipRanks >>
Learn Extra on VXRT: